Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

Javier Pinilla-Ibarz, Jorge Cortes, Michael J. Mauro

Research output: Contribution to journalReview article

45 Scopus citations

Abstract

Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region-Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long-term imatinib therapy; however, the availability of the second-generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long-term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML-specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients.

Original languageEnglish (US)
Pages (from-to)688-697
Number of pages10
JournalCancer
Volume117
Issue number4
DOIs
StatePublished - Feb 15 2011
Externally publishedYes

    Fingerprint

Keywords

  • dasatinib
  • imatinib
  • intolerance
  • nilotinib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this